LENZ Therapeutics, Inc. 8-K

What Happened
LENZ Therapeutics, Inc. filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on June 12, 2026. Of 31,354,394 shares outstanding as of the April 14, 2026 record date, 24,442,068 shares (≈77.96%) were represented at the meeting. The company elected three Class II directors and stockholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year 2026.

Key Details

• Record date and turnout: 31,354,394 shares outstanding (April 14, 2026); 24,442,068 shares represented at the meeting (≈77.96%).
• Director election results:
  • Evert Schimmelpennink — For: 20,216,637; Withheld: 230,219; Broker non-votes: 3,995,212.
  • Jeff George — For: 13,462,359; Withheld: 6,984,497; Broker non-votes: 3,995,212.
  • Shelley Thunen — For: 20,215,686; Withheld: 231,170; Broker non-votes: 3,995,212.
• Auditor ratification: Ernst & Young LLP ratified as independent auditor for 2026 — For: 24,310,915; Against: 55,181; Abstentions: 75,972.

Why It Matters
The filing confirms the company’s board composition for the next term and continues engagement with Ernst & Young as auditor for fiscal 2026. Investors may note the relatively large number of withheld votes for nominee Jeff George compared with the other directors (6.98 million withheld vs. 13.46 million For), and the presence of roughly 4.0 million broker non-votes on the director elections; these vote patterns can signal differing shareholder views on specific board nominees. The auditor ratification provides continuity for financial reporting oversight for the coming year.